CLAIMS

1. Use of a compound having the following structure (1):

(1)



its diastereomer, enantiomer, racemic mixture, salts or a combination thereof, in the manufacture of a medicament for treatment of one or more sodium channel related diseases or disorders in an individual, wherein R is selected from a group comprising hydrogen, alkyl, alkenyl, alkoxy, halo, nitro, cyano, keto, amino, carboxylate, substituted or unsubstituted phenyls, adjacent rings which share a side with the R-bearing group, or a combination thereof, wherein the one or more sodium channel related diseases or disorders is bronchospasm, oesophageal spasm, irritable bowel syndrome (IBS), urinary incontinence or cancer.

2. Use of the compound according to claim 2, wherein the R-bearing group is mono-, di-, or tri-substituted.

3. Use of the compound according to claim 1 or 2, wherein the compound is a threo-diastereomer, a erythro-diastereomer or a mixture of the threo-diastereomer and the erythro-diastereomer.

4. Use of the compound according to any one of claims 1 to 3, wherein R is one or more substituents selected from the group consisting of hydrogen, halogens, substituted or unsubstituted phenyls, and adjacent rings which share a side with the R-bearing group.

5. Use of the compound according to any one of claims 1 to 4, wherein R consists of chlorine substituents at positions 3 and 4.

6. Use of the compound according to any one of claims 1 to 4, wherein R is a *p*-bromo.

7. Use of the compound according to any one of claims 1 to 4, wherein R is a *p*-chloro.

8. Use of the compound according to any one of claims 1 to 4, wherein R is a p-2-naphthyl.

9. Use of the compound according to any one of claims 1 to 4, wherein R is an unsubstituted *p*-phenyl.

10. Use of the compound according to claim 9, wherein the compound has the following structure (2):

(2)



11. Use of the compound according to claim 9, wherein the compound has the following structure (3):

(3)



12. Use of the compound according to claim 9, wherein the compound comprises mixture of structures (2) and (3).

13. Use of the compound according to any one of claims 1 to 12, wherein the compound is capable of inhibiting sodium channel conductance.

14. Use of the compound according to claim 13, wherein the sodium channels are voltage gated sodium channels.

15. Use of the compound according to any one of claims 1 to 14, wherein the compound is capable of inhibiting serotonin receptors and reducing the activity of serotonin receptors.

16. Use of the compound according to any one of claims 1 to 15, wherein the compound is administered orally, parenterally, intramuscularly, intravenously, mucosally or transdermally.

17. Use of the compound according to any one of claims 1 to 16, wherein the use further includes alleviating one or more symptoms of the one or more sodium channel related diseases or disorders, wherein the symptoms include pain, convulsion and inflammation.

18. Use of a composition comprising a compound according to any one of claims 1 to 17 and a pharmaceutical acceptable carrier in the manufacture of a medicament for treatment of one or more sodium channel related diseases or disorders in an individual, wherein the one or more sodium channel related diseases or disorders is bronchospasm, oesophageal spasm, irritable bowel syndrome (IBS), urinary incontinence or cancer.